CORCYM, the new medical device company, enters the market today with state-of-the-art surgical solutions to fight structural heart disease.

CORCYM announces the enrollment of the first patient in the MANTRA study. It is planned to enroll 1,750 patients in about 100 centers worldwide.

About CORCYM CORCYM is a global, independent, medical device company entirely focused on state-of-the-art surgical solutions to fight structural heart disease.

This allows Corcym to commercialise the grafts, RUA Life Sciences said. "The mutual benefits of this partnership with Corcym are transformational for RUA," said RUA Life Sciences Chair Bill Brown.

CORCYM, the new, independent, medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the enrollment ...